Patents by Inventor Eddie Carroll

Eddie Carroll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060179496
    Abstract: This invention relates to novel nucleic acid sequences which are differentially expressed in cancer cells. The invention also relates to proteins and peptides encoded by the sequences, to diagnostic assays and therapeutic agents based on the sequences and proteins, and to probes, antisense constructs, and antibodies derived from the sequences and proteins or peptides. The subject nucleic acids have been found to be differentially expressed by tumor cells, particularly in colon cancer tissue.
    Type: Application
    Filed: July 26, 2005
    Publication date: August 10, 2006
    Inventors: Christopher Burgess, Jon Astle, Eddie Carroll, Theodore Catino, Poornima Dwivedi, Gary Molino, Arunthathi Thiagalingam, Marcia Lewis, Stephen Thibodeau, Lawrence Burgart, Lisa Boardman
  • Publication number: 20040110668
    Abstract: This invention relates to novel nucleic acid sequences which are differentially expressed in cancer cells. The invention also relates to proteins and peptides encoded by the sequences, to diagnostic assays and therapeutic agents based on the sequences and proteins, and to probes, antisense constructs, and antibodies derived from the sequences and proteins or peptides. The subject nucleic acids have been found to be differentially expressed by tumor cells, particularly in colon cancer tissue.
    Type: Application
    Filed: October 2, 2001
    Publication date: June 10, 2004
    Inventors: Christopher C. Burgess, Jon H. Astle, Eddie Carroll, Theodore J. Catino, Poornima Dwivedi, Gary A. Molino, Arunthathi Thiagalingam, Marcia E. Lewis
  • Publication number: 20030097666
    Abstract: This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic assays and therapeutic agents related to the genes and proteins, including probes, antisense constructs, and antibodies. The subject nucleic acids have been found to be differentially regulated in tumor cells, particularly in colon cancer tissue.
    Type: Application
    Filed: May 31, 2001
    Publication date: May 22, 2003
    Inventors: Wilson O. Endege, Kathleen E. Steinmann, Jon H. Astle, Christopher C. Burgess, Eddie Carroll, Theodore J. Catino, Poornima Dwivedi, Donna M. Ford, Marcia E. Lewis, Gary A. Molino, John E. Mohahan, Robert Schlegel
  • Publication number: 20020192699
    Abstract: This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic and therapeutic agents related to the genes and proteins, including probes, antisense constructs, and antibodies. The invention further relates to polynucleotides differentially expressed in prostate cancer.
    Type: Application
    Filed: July 23, 2002
    Publication date: December 19, 2002
    Applicant: Chiron Corporation
    Inventors: Jimmy Zhang, Jon H. Astle, Eddie Carroll, Wilson O. Endege, Donna M. Ford, John E. Monahan, Robert Schlegel, Kathleen E. Steinmann
  • Patent number: 6476207
    Abstract: This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic and therapeutic agents related to the genes and proteins, including probes, antisense constructs, and antibodies. The invention further relates to polynucleotides differentially expressed in prostate cancer.
    Type: Grant
    Filed: June 9, 1999
    Date of Patent: November 5, 2002
    Assignee: Chiron Corporation
    Inventors: Jimmy Zhang, Jon H. Astle, Eddie Carroll, III, Wilson O. Endege, Donna M. Ford, John E. Monahan, Robert Schlegel, Kathleen E. Steinmann
  • Publication number: 20020144298
    Abstract: This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic assays and therapeutic agents related to the genes and proteins, including probes, antisense constructs, and antibodies. The subject nucleic acids have been found to be differentially regulated in tumor cells, particularly colon cancer cell lines and/or tissue.
    Type: Application
    Filed: June 11, 2001
    Publication date: October 3, 2002
    Inventors: Wilson O. Endege, Kathleen E. Steinmann, Jon H. Astle, Christopher C. Burgess, Steven E. Bushnell, Eddie Carroll, Theodore J. Catino, Adnan Derti, Donna M. Ford, Marcia E. Lewis, John E. Mohahan, Robert Schlegel
  • Patent number: 6262333
    Abstract: This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic assays and therapeutic agents related to the genes and proteins, including probes, antisense constructs. and antibodies. The subject nucleic acids have been found to be differentially regulated in tumor cells, particularly colon cancer cell lines and/or tissue.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: July 17, 2001
    Assignee: Bayer Corporation
    Inventors: Wilson O. Endege, Kathleen E. Steinmann, Jon H. Astle, Christopher C. Burgess, Steven E. Bushnell, Eddie Carroll, III, Theodore J. Catino, Adnan Derti, Donna M. Ford, Marcia E. Lewis, John E. Monahan, Robert Schlegel
  • Patent number: 6262334
    Abstract: This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic assays and therapeutic agents related to the genes and proteins, including probes, antisense constructs, and antibodies. The subject nucleic acids have been found to be differentially regulated in tumor cells, particularly in colon cancer tissue.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: July 17, 2001
    Assignee: Bayer Corporation
    Inventors: Wilson O. Endege, Kathleen E. Steinmann, Jon H. Astle, Christopher C. Burgess, Eddie Carroll, III, Theodore J. Catino, Poornima Dwivedi, Donna M. Ford, Marcia E. Lewis, Gary A. Molino, John E. Monahan, Robert Schlegel
  • Patent number: 6083689
    Abstract: A novel signal amplification system for immunoassays that minimizes non-specific signals is disclosed. Immunoassay methods, reagents and test kits are described for obtaining immunoassays of enhanced sensitivity. The reagents include antibody-variant DNA conjugates, wherein the variant DNA is a substrate for an RNA-dependent RNA polymerase, such as, QB replicase. Immunoassay methods to detect, or to detect and quantitate, analyte in test samples comprise transcribing the variant DNA of said antibody-DNA conjugates that are bound to analyte, to RNA, and replicating the RNA transcripts, wherein the presence or quantity of variant RNA replication products can be correlated with the presence or quantity of analyte in the test samples. Further, methods are provided to detect, or to detect and quantitate, simultaneously two or more analytes in a test sample.
    Type: Grant
    Filed: April 4, 1995
    Date of Patent: July 4, 2000
    Assignee: Bayer Corporation
    Inventors: Richard A. Martinelli, Eddie Carroll, III
  • Patent number: 5783453
    Abstract: The assay described herein is predicated on an observation that when acridinium ester labeled tracers are bound to their corresponding binding conjugate immobilized on a metal oxide solid phase, the measurable chemiluminescent light emission of the labeled tracer bound to the solid phase is quenched as compared to the free fraction tracer that is unattached to the solid phase. According to the invention, a non-separation specific binding assay to detect or quantify the presence of an analyte is provided where the entire reaction mixture is flashed (including unreacted tracer) and modulated signal (because of the quench effect) is associated with a reference, thus determining the amount or presence of said analyte in said sample. Disadvantages inherent in heterogeneous assays employing multiple separations may be avoided using this non-separation method.
    Type: Grant
    Filed: June 29, 1995
    Date of Patent: July 21, 1998
    Assignee: Chiron Diagnostics Corporation
    Inventors: Eve H. Barlow, Eddie Carroll, III, Joseph E. Connolly, Michael J. Lee, Richard A. Martinelli, John T. Unger